22 clinical trials matched your search for Kidney Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Kidney Cancer Study of Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma Karie D. Runcie, MD
Kidney Cancer Cyto-KIK Trial: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition Mark Stein, MD
Kidney Cancer Study of XmAb819 in Patients with Clear Cell Renal Cell Carcinoma Karie D. Runcie, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Hua-Jay Cherng, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors Benjamin Izar, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD
Cancer Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors Ryan Moy, MD
Cancer Study of XmAb808 in Combination with Pembrolizumab in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of AMG 193 and IDE397 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of PRT3789 in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Benjamin Herzberg, MD
Cancer Study of RMC-6291 and RMC 6236 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RP-1664 in Patients with Solid Tumors Benjamin Herzberg, MD